Intended Audience: Hematology/oncology teams, including physicians, NPs/PAs, pharmacists, nurses, and case managers, in the federal and public health settings

New advances in treatment for Myelodysplastic Syndromes, Myelofibrosis, and Acute Myeloid Leukemia are poised to transform outcomes for patients with these hematologic malignancies. In this live webinar, hear leading experts discuss the latest evidence along with case examples for application to clinical practice.

This webinar is delivered in partnership with AMSUS, The Society of Federal Health Professionals.

• Evaluate the role of molecular, predictive, and prognostic factors in guiding treatment decisions for patients with hematologic malignancies
• Discuss current evidence and guidelines for the diagnosis, treatment, and management of hematologic malignancies
• Assess new safety and efficacy data guiding the optimal use of targeted agents and immunotherapies in appropriate patients

I. Integrating validated risk-scoring tools into patient evaluation and prognostic assessment

II. Integrating the latest evidence and clinical guidelines into treatment decision-making

III. Case-based discussions in myelodysplastic syndromes, myelofibrosis, and acute myeloid leukemia

1. Register using the online form
2. Complete the pre-registration survey
3. Attend the live program in its entirety
4. Complete an online evaluation and post-test
5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

• Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
• Software: the installation of software such as GoToWebinar may be required

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

• Joshua F Zeidner, MD (Speaker)
  
  Advisory Board or Panel – Astex, Bristol-Myers Squibb, Genentech, Servier, Shattuck Labs
  Consultant – AbbVie, Astex
  Grants / Research Support – Arog, Astex, Genentech, Servier, Tolero
• Daniel A Pollyea, MD, MS (Speaker)
  
  Advisory Board or Panel – AbbVie, Amgen, Aprea, Astellas, Bristol-Myers Squibb, Celgene, Foghorn, Genentech, Gilead Sciences, Jazz, Karyopharm, Kiadis, Novartis, Syndax, Syros, Takeda
  Consultant – AbbVie, Amgen, Aprea, Astellas, Bristol-Myers Squibb, Celgene, Foghorn, Genentech, Gilead Sciences, Glycomimetics, Karyopharm, Kiadis, Novartis, Syndax, Syros, Takeda
  Grants / Research Support – AbbVie, Karyopharm, Teva Pharmaceuticals
• João L Ascensão, MD, PhD, FACP (Course Director, Speaker)
  
  Advisory Board or Panel – Incyte
• Manali I Patel, MD, MPH, MS (Speaker)
  
  Consultant – Celgene, ThymeCare
• Paul M Barr, MD (Speaker)
  
  Consultant – AbbVie, AstraZeneca, Celgene, Genentech, Janssen, Merck, Pharmacyclics, Seattle Genetics, TG therapeutics, Verastem
  Grants / Research Support – AstraZeneca, TG therapeutics
• Susan M O'Brien, MD (Speaker)
  
  Consultant – Abbie, Alexion, Amgen, Aptose Biosciences, Astellas, Autolus, Bristol-Myers Squibb, Celgene, DynaMed, Eli Lilly and Company, GlaxoSmithKline, Janssen Oncology, Johnson & Johnson, Juno Therapeutics, MEI Pharma Inc., Merck, NOVA Research Company, Pfizzer, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, Vida Ventures
  Grants / Research Support – Acerta, Autolus, Caribou, Gilead Sciences, Kite, Pfizzer, Pharmacyclics, Sunesis, TG Therapeutics
• Caron A Jacobson, MD (Speaker)
  
  Advisory Board or Panel – AbbVie, BMS/Celgene, Kite/Gilead Sciences, Lonza, Nkarta, Novartis, Precision Biosciences
  Consultant – AbbVie, BMS/Celgene, Kite/Gilead Sciences, Lonza, Nkarta, Novartis, Precision Biosciences
  Grants / Research Support – Kite/Gilead Sciences, Pfizer
  Speakers Bureau or other Promotional Education – BMS/Celgene
• Peter Martin, MD (Speaker)
  
  Advisory Board or Panel – Beigene, Takeda
  Consultant – ADCT, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Cellectar, Epizyme, Gilead Sciences, Incyte, Janssen, Karyopharm, Merck, Morphosys, Regeneron, Teneobio, Verastem
  Grants / Research Support – Karyopharm
• Joseph R Mikhael, MD, MEd, FRCPC, FACP (Speaker)
  
  Consultant – Amgen, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi, Takeda
• Rafael Fonseca, MD (Speaker)
  
  Advisory Board or Panel – Adaptive Biotechnologies, OncoTracker
  Consultant – AbbVie, Aduro, Amgen, Bayer, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, OncoTracker, Pharmacyclics, Sanofi, Takeda
• William Wachsman, MD, PhD (Moderator)
  
  Consultant – Curio Inc.
  Stock / Shareholder (self- managed) – Prudential Inc.
• Larry D Anderson, Jr, MD, PhD (Speaker)
  
  Advisory Board or Panel – Amgen, Bristol Myers Squibb/Celgene, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides
  Consultant – Amgen, Bristol Myers Squibb/Celgene, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides

The following individuals have no relevant financial relationships with commercial interests to disclose:

• Ryan J Atkinson, PharmD, MBA (Moderator)
• Michele B Kaufman, PharmD, BCGP (Reviewer)
• Joyce M Knestrick, PhD, CRNP, FAANP (Planner)
• Mark A Rubin, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.